FDA-cleared profile

CogNet AI-MT+

Medcognetics, Inc. · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Prioritizes suspicious screening DBT examinations for MQSA interpreting physicians; every examination remains subject to full physician review.

Clinical role
Passive-notification, prioritization-only triage tool running in parallel with standard workflow: it analyzes DBT screening mammograms and sends an exam-level suspicious flag to the PACS/workstation for worklist prioritization, without removing images from the worklist or providing diagnostic information.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Passive triage only, not diagnostic information; output cannot remove images or replace MQSA physician review and is limited to validated Hologic Dimensions DBT input.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Prioritizes suspicious screening DBT examinations for MQSA interpreting physicians; every examination remains subject to full physician review.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Four bilateral DICOM For Presentation DBT views from Hologic Selenia Dimensions; validation excluded breast implants and post-surgical studies.
  • Who uses it?Intended users: MQSA interpreting physicians
  • What does the software produce?Output: DICOM Secondary Capture and private DICOM tags with Suspicious/red-diamond or Processed/blue-circle status; no diagnostic viewer is supplied.
  • What is its most important limitation?Key limitation: Passive triage only, not diagnostic information; output cannot remove images or replace MQSA physician review and is limited to validated Hologic Dimensions DBT input.

Clinical takeaway. Clinical role: Prioritizes suspicious screening DBT examinations for MQSA interpreting physicians; every examination remains subject to full physician review.

Evidence takeaway. Evidence from the reviewed source record: The FDA summary reports a standalone retrospective diagnostic-enriched DBT study; no general-population screening performance claim is made.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Prioritizes suspicious screening DBT examinations for MQSA interpreting physicians; every examination remains subject to full physician review.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Passive-notification, prioritization-only triage tool running in parallel with standard workflow: it analyzes DBT screening mammograms and sends an exam-level suspicious flag to the PACS/workstation for worklist prioritization, without removing images from the worklist or providing diagnostic information.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The MedCognetics CogNet AI-MT+ software is a passive notification for prioritization- only, parallel-workflow software tool used by MQSA qualified interpreting physicians to prioritize patients with suspicious findings" … "to analyze DBT screening mammograms and flags those that are suggestive of the presence of at least one suspicious finding at the exam level. CogNet AI-MT+ produces an exam level output to a PACS/Workstation for flagging the suspicious study and allows for worklist prioritization.". Read from the exact FDA decision document on 2026-11-14.

Required input
Four bilateral DICOM For Presentation DBT views from Hologic Selenia Dimensions; validation excluded breast implants and post-surgical studies.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
DICOM Secondary Capture and private DICOM tags with Suspicious/red-diamond or Processed/blue-circle status; no diagnostic viewer is supplied.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
MQSA interpreting physicians
  • Exact FDA submission
  • Checked 2026-09-19

The exact device description states that the software tool is for MQSA interpreting physicians reading mammograms.

Limitations
Passive triage only, not diagnostic information; output cannot remove images or replace MQSA physician review and is limited to validated Hologic Dimensions DBT input.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Evidence summary
The FDA summary reports a standalone retrospective diagnostic-enriched DBT study; no general-population screening performance claim is made.
  • Exact FDA submission
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The FDA summary reports a standalone retrospective diagnostic-enriched DBT study; no general-population screening performance claim is made.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported sensitivity
88.09
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Standalone retrospective endpoint; study context applies.

Reported specificity
91.56
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Standalone retrospective endpoint; study context applies.

Sensitivity

0.8809 proportion

  • EndpointStandalone suspicious-exam triage classification
  • Population806 women; 403 biopsy-proven malignancy and 403 benign/negative reference cases
  • Tested versionCogNet AI-MT+

Specificity

0.9156 proportion

  • EndpointStandalone suspicious-exam triage classification
  • Population806 women; 403 biopsy-proven malignancy and 403 benign/negative reference cases
  • Tested versionCogNet AI-MT+

CogNet AI-MT+ regulatory standalone DBT evaluation

  • DesignRetrospective standalone diagnostic-enriched evaluation.
  • Population806 women using Hologic Selenia Dimensions DBT; 50% cancer-enriched.
  • Scopeexact submission
  • Tested versionCogNet AI-MT+
  • Samplen=806
  • IndependenceIndependence not established

K252482

Not representative of screening prevalence.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Four bilateral DICOM For Presentation DBT views from Hologic Selenia Dimensions; validation excluded breast implants and post-surgical studies.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K252482: CogNet AI-MT+

  2. Routing

    Source context, not route validation: Input may be routed from PACS, modality or a DICOM router; output may populate an API worklist column.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · CogNet AI-MT+: K252482 clearance and 510(k) summary

  3. AI processing

    Source context, not route validation: Cloud-based licensed access is described in the summary.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 · CogNet AI-MT+: K252482 clearance and 510(k) summary

  4. Returned objects

    Source context, not route validation: DICOM Secondary Capture and private DICOM tags with Suspicious/red-diamond or Processed/blue-circle status; no diagnostic viewer is supplied.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K252482: CogNet AI-MT+

  5. Viewer/worklist/report

    Unresolved route: DICOM Secondary Capture and private DICOM tags with Suspicious/red-diamond or Processed/blue-circle status; no diagnostic viewer is supplied.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K252482: CogNet AI-MT+

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Cloud-based licensed access is described in the summary.
  • Exact FDA submission
  • Checked 2026-09-05
Integration
Input may be routed from PACS, modality or a DICOM router; output may populate an API worklist column.
  • Exact FDA submission
  • Checked 2026-09-05
Training
Licensed users receive a user manual and quality/technical staff provide initial usage support.
  • Exact FDA submission
  • Checked 2026-09-05

Current family scope note

The vendor's embedded AI material is labeled investigational and is not treated as a cleared deployment capability for CogNet AI-MT+.

product family · checked 2026-09-05
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252482
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-12-11
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-19Last searched
28Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

No stored literature or trial candidates; empty metadata snapshots were screened. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-06 - Exact product version
  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "MedCognetics mammography AI reimbursement"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No result was a vendor or payer page naming this product with coding or payment; any results were general billing guidance. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-05 - Exact product version

    Technical controls in the summary do not establish a current formal security attestation.

  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K252482: CogNet AI-MT+

    U.S. Food and Drug Administration - Published 2025-12-11 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, input, output, limitations, intendedUsers, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. CogNet AI-MT+ model card (K252482)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. CogNet AI-MT+: K252482 clearance and 510(k) summary

    US Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinical, implementation, evidence

  8. MedCognetics embedded AI

    MedCognetics - Accessed 2026-09-05

    Scope: product_family_scope_limit

Research history

  1. K252482 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04
FDA-cleared K233108

VinDr-Mammo

VinBigData Joint Stock Company

The VinDr-Mammo is a passive notification for prioritization-only, a parallel- workflow software tool used by MQSA qualified interpreting physicians to prioritize patients with suspicious findings in the medical care environment. VinDr-Mammo utilizes an artificial intelligence algorithm to analyze 2D FFDM screening mammograms and flags those that are suggestive of the presence of at least one suspicious finding at the exam- level. VinDr-Mammo produces an exam-level output to a PACS/Workstation for flagging the suspicious case and allows worklist prioritization. MQSA qualified interpreting physicians are responsible for reviewing each exam on a display approved for use in mammography, according to the current standard of care. VinDr-Mammo device is limited to the categorization of exams, does not provide any diagnostic information beyond triage and prioritization, does not remove images from the interpreting physician’s worklist, and should not be used in lieu of full patient evaluation, or relied upon to make or confirm diagnosis. The VinDr-Mammo device is intended for use with complete 2D FFDM mammography exams acquired using validated FFDM systems only.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2024-05-23
FDA-cleared K220080

CogNet QmTRIAGE

MedCognetics, Inc.

Authorized purpose: Passive exam-level notification and prioritization of suspicious findings in screening mammograms.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2022-09-29
FDA-cleared K203517

Saige-Q

DeepHealth, Inc.

Authorized purpose: Provides passive worklist prioritization for compatible FFDM and DBT screening mammograms.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2021-04-16

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history